AI-assisted Migraine Education: Efficacy, Safety and Patients' Acceptance
ConditionMigraine
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorEnte Ospedaliero Cantonale, Bellinzona
About this trial
Migraine affects 1 in 7 people globally, significantly impacting quality of life and economic productivity. Despite its prevalence, limited awareness leads to misdiagnosis, inadequate treatment, and stigmatization. AI can enhance migraine management through improved diagnosis, prediction, and personalized education. The primary objective of this study is to determine if adding AI-assisted migraine education to standard education improves patients' understanding of their condition more effectively.
Eligibility criteria
Qualifiers
aged between 18 and 65 years at the time of signing the informed consent
Newly diagnosis of migraine, confirmed through the medical chart
The participant must be capable of giving signed informed consent
Access to a laptop, computer, smartphone, or tablet
Disqualifiers
Insufficient knowledge of the protocol language (italian)
Patients with cognitive impairment and/or unable to use or access the AI-powered learning platform developed in this study.
Vulnerable participants (e.g. minors, participants incapable of judgment or participants under tutelage)
Trial design
Treatments tested in this trial
- AI-assisted migraine education (AIME)
Treatment groups
140 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov